Psygen’s progressive business model is primarily focused on the large-scale manufacture of GMP psychedelic APIs. With existing Contract Manufacturing Organizations (CMOs) lacking expertise and infrastructure to produce at scale – and often manufacturing in non-dedicated facilities under restrictive exclusivity agreements — the current supply chain is insufficient to meet the industry’s growing needs.
A World-Leading Psychedelic Supply Chain Solution
Psygen has established the infrastructure necessary to meet projected demand through to 2025, completing phase 1 of our strategic plans. We now embark on phase 2 – scaling to meet global, commercial demand while improving environmental sustainability.
Ryan Zurrer of Vine Ventures interviews Peter van der Heyden & Danny Motyka, discussing their founding vision.
Ryan, one of Psygen’s initial investors who has a significant shareholder position, has been a venture capitalist for a decade. Ryan launched Vine Ventures in 2019 to invest broadly across the emerging psychedelics landscape. Vine is the leading venture firm in psychedelics.